Table 1: Clinical outcomes of oral steroid method of preventing esophageal stricture after endoscopic resection.

Author, yearDesignSettingSample size
(treated/control)
Follow-upStricture rateMean or median number of EBDAdverse event

Lizuka, 2018 [25]Retrospective cohort studyESD
100%
SEC
11/11Gastroscopy: 1, 4, 8, 12, 16, and 20 weeks after ESD36.4%VS 82%
(P=0.04)
6.2 VS 19.4
(P=0.023)
8 VS 3
(P=0.043)
Zhou, 2017 [26]Retrospective cohort studyESD
>75%
ESCC
13/10Gastroscopy: 1, 3, 6, and 12 months after ESD23.1%VS 80%
(P=0.007)
0.69 VS 13.5
(P=0.004)
None
Jean-Philippe,2017 [27]Single-center retrospective studyEMR
>50%
Barrett’s esophagus
29/0Gastroscopy: 2, 6, 12, and 24 months after EMR13%2None
Mikinori, 2015[23]
Retrospective cohort studyESD
>75%
ESCC
17/16Gastroscopy: 8 weeks after ESD17. 6%VS
68.7%
P<0.01
4.6 VS 8.1
P<0.01
None
Hiroki, 2013 [24]Retrospective cohort studyESD
100%
SEC
10/13Gastroscopy: 7 days, 2-, 3-, and 4-week interval until week after negative endoscopyBoth 100%13.8 VS 33.5
P<0.001
None
Naoyuki, 2011 [28]Case reportESD
100%
ESCC
1/0Gastroscopy: 1, 3, and 6 months after ESD0%0None
Hajime, 2011 [29]Retrospective studyESD
100%
ESCC
4/3Gastroscopy: 3, 6, and 12 months after ESD and then annually thereafterBoth 100%3.25 VS 32.67
(P<0.05)
None
Naoyuki, 2011 [22]Retrospective studyESD
>75%
ESCC
19/22Gastroscopy: 1, 3, 6, and 12 months after ESD and then annually thereafter5.3%VS31.8%
(P=0. 03)
1.7 VS 15.6
(P<0. 0001)
None

SEC, superficial esophageal cancer; ESCC, esophageal squamous cell carcinomas.